(Q44297418)

English

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Roger S Kirby

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Claus Roehrborn

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Georg Bartsch

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Alain Jardin

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Margaret M Cary

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Michael Sweeney

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Eric B Grossman

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Prospective European Doxazosin and Combination Therapy Study Investigators

9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

61

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

119-126

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902114-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(02)02114-3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44297418&oldid=2109255715"